Clinical Trial to Evaluate the Efficacy and Safety of EEC for the Diagnosis of Mycobacterium Tuberculosis Infection in People Aged 3 Years and Above

CoenBiotech

Status and phase: Enrolling; Phase 3

Conditions: Tuberculosis

Treatments: Biological: 5μg/ml EEC; Diagnostic Test: IGRA; Biological: 5 unit（U） EC; Biological: 5 IU TB-PPD

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07152639

KN-EEC-III

Details and patient eligibility

About

This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above.

Methods: In study 1, the marketed recombinant Mycobacterium tuberculosis fusion protein (EC) was used as a control drug in people aged 3 to 64 years. The sensitivity of EEC in participants with tuberculosis and the specificity in healthy participants and patients with non-tuberculous lung diseases were evaluated compared with recombinant Mycobacterium tuberculosis fusion protein (EC). The clinical positivity criteria of EEC were verified, and the consistency of the two detection methods, as well as the safety of EEC, were evaluated.

Study 2: Triple-negative people aged 18 and above (negative in EEC, TB-PPD, and IGRA tests) were screened out from the community population and vaccinated with BCG. EEC and TB-PPD double-arm skin tests were performed 12 weeks after vaccination to evaluate whether there was a significant difference in the negative rate of EEC compared with TB-PPD after BCG vaccination in the triple-negative population.

Study 3: A multicenter, positive-controlled, non-inferiority trial design was used for people aged 65 years and above, and the research hypothesis was independently tested to verify the non-inferiority of the sensitivity of this product in tuberculosis patients in this age group compared with IGRA and TB-PPD, as well as the consistency of the diagnostic results of IGRA with non-tuberculous lung diseases and the general community population. At the same time, attention was paid to and analysis of the specificity and safety of EEC in people aged 65 years and above.

Full description

This study is a randomized, blinded, active-controlled clinical trial to evaluate the effectiveness and safety of EEC in the diagnosis of Mycobacterium tuberculosis infection in people aged 3 years and above.

Study 1: The marketed recombinant tuberculosis fusion protein (EC) was used as a control drug in the population aged 3-64 years: This clinical trial adopted a multicenter, randomized, positive-controlled, blinded, homologous double-arm, non-inferiority trial design in the population aged 3-64 years, aiming to evaluate the sensitivity of EEC compared with recombinant tuberculosis fusion protein (EC) in participants with tuberculosis, the specificity in healthy participants and patients with non-tuberculous lung diseases, verify the clinical positive judgment criteria of EEC, and evaluate the consistency of the two detection methods of EEC and EC and the safety of EEC.

Study 2: The marketed tuberculin purified protein derivative (TB-PPD) was used as a control drug in the triple-negative population aged 18 years and above:

The triple-negative population (EEC, TB-PPD, and IGRA tests were all negative) was screened out from the community population and vaccinated with BCG. After 12 weeks of vaccination, EEC and TB-PPD were tested in the same arm to evaluate the significant difference in the negative rate of EEC compared with TB-PPD in the triple-negative population after BCG vaccination.

Study 3: TB-PPD and in vitro diagnostic reagent IGRA were used as controls for people aged 65 and above:

For people aged 65 and above, a multicenter, positive control, non-inferiority trial design was used to conduct a separate study hypothesis to verify the non-inferiority of the sensitivity of this product in tuberculosis patients in this age group compared with IGRA and TB-PPD, as well as the consistency of the diagnostic results of non-tuberculous lung diseases and the general community population with IGRA. At the same time, the specificity and safety of EEC in people aged over 65 were analyzed.

Enrollment: 1,784 estimated patients

Sex: All

Ages: 3+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• For the general community population

  1. Age 3 years and above at the time of enrollment, regardless of gender;
  2. The individual and/or guardian agree to participate in this trial and sign the informed consent form;
  3. The individual and/or guardian can comply with the requirements of the clinical trial protocol to participate/accompany the participants to participate in follow-up;
  4. No history of tuberculosis (including intrapulmonary and extrapulmonary tuberculosis) after medical history inquiry;
  5. No clinical symptoms of tuberculosis poisoning. Tuberculosis poisoning symptoms refer to obvious systemic symptoms such as fatigue, low fever in the afternoon, loss of appetite, night sweats, etc. in addition to local symptoms such as cough, chest pain, and chest tightness. Women may have endocrine system disorders, such as irregular menstruation, amenorrhea, etc.;
  6. Inclusion criteria for triple-negative population: People with negative results of the first skin test on both arms and IGRA test results (i.e., negative results of EEC, TB-PPD, and IGRA tests).

• For Patients with tuberculosis (including pulmonary tuberculosis)

  1. Age 3 years and above at the time of enrollment, regardless of gender;
  2. Participants aged ≥18 years were diagnosed with tuberculosis/pulmonary tuberculosis according to the diagnostic standard "Standard Tuberculosis Classification of the Health Industry of the People's Republic of China WS196-2017" issued by the health and health authorities of the State Council (recognizing the diagnosis made by comprehensive clinical analysis); participants aged 3-17 years were diagnosed with tuberculosis according to the "Expert Consensus on Diagnosis of Childhood Pulmonary Tuberculosis (2022 Edition)" formulated by the Children's Tuberculosis Professional Committee of the Tuberculosis Branch of the Chinese Medical Association. Including pulmonary tuberculosis and extrapulmonary tuberculosis, of which pulmonary tuberculosis includes bacteria-negative/bacteria-positive pulmonary tuberculosis and primary/relapsed pulmonary tuberculosis; patients with both pulmonary tuberculosis and extrapulmonary tuberculosis can be included and classified as pulmonary tuberculosis;
  3. The individual and/or guardian agree to participate in this trial and sign the informed consent form;
  4. The individual and/or guardian can comply with the requirements of the clinical trial protocol to participate in follow-up.

For Patients with non-tuberculous lung disease

1. Patients with a clear clinical diagnosis of non-tuberculous lung disease, and clinical physicians can exclude pulmonary tuberculosis and extrapulmonary tuberculosis based on the patient's clinical manifestations, imaging and laboratory tests, including pneumonia, lung cancer, bronchitis, bronchiectasis, non-tuberculous mycobacterial disease, chronic obstructive pulmonary disease, etc.;
2. Aged 3 years and above at the time of enrollment, regardless of gender;
3. The individual and/or guardian agree to participate in this trial and sign the informed consent form;
4. The individual or guardian can comply with the requirements of the clinical trial protocol to participate in follow-up.

Exclusion criteria

- For the general community population

1. Those with known or suspected (or high-risk) severe immune diseases, immune function damage or abnormalities (Except for human immunodeficiency virus [HIV] infection/HIV infection), including:Those who received immunosuppressants (including chemotherapy) (using medium/high doses of glucocorticoids (≥20mg/d or ≥0.5mg/kg/d prednisone or equivalent other hormones), and the medication time was >14 days) or immunopotentiators within 3 days before the skin test or during the trial, and those who were evaluated by the researchers to affect the efficacy of the participants; Note: For glucocorticoid drugs: topical inhalation, nasal spray, local injection, application and other external use, as well as long-term physiological replacement therapy for systemic medication such as oral, intramuscular injection, intravenous injection or intravenous drip, there are no restrictions, such as prednisone or other equivalent doses of other drugs with a dose of <20mg/d (>5 years old) or <0.5mg/kg/d (≤5 years old), and the medication time is ≤14 days.
2. Patients with convulsions, epilepsy, history of mental illness and/or family history of mental illness (immediate relatives);
3. Patients with allergic constitution, such as those with a history of allergy to two or more drugs or foods, or those known to be allergic to the components of this drug;
4. Patients with acute infectious diseases (such as measles, whooping cough, influenza, etc.), acute conjunctivitis, acute otitis media, and extensive skin diseases;
5. Patients with acute febrile diseases; or those who have used antipyretic, analgesic and antiallergic drugs within 3 days before the skin test and who have been assessed by the researchers to be likely to affect the study evaluation;
6. Patients with severe skin infections (such as pyoderma, severe eczema, etc.);
7. Those who have used other clinical trial drugs within 3 months before the skin test (except placebo, in vitro diagnostic reagents or non-contact human devices);
8. Those who have received inactivated vaccines within 7 days before the skin test, or attenuated live vaccines within 28 days;
9. Women who are breastfeeding or pregnant, or women of childbearing age who have a positive pregnancy test before enrollment. 10) Those with a history of drug abuse;

11) Those who the researcher believes have poor compliance, past history, physical examination results that may affect the trial evaluation (such as tattoos, etc.); 12) Exclusion criteria for triple-negative population: Those with contraindications to BCG vaccination, including: ① Those with immunodeficiency or damage (such as AIDS patients); ② Those currently using immunosuppressive drugs or radiotherapy; ③ Those who are allergic to BCG; ④ Those with fever and acute infectious diseases, including active tuberculosis patients; ⑤ Severe chronic diseases (such as heart, brain, vascular diseases, chronic kidney disease).

For Patients with tuberculosis and non-tuberculous lung disease

1. Those with known or suspected (or high-risk) severe immune diseases, immune function damage or abnormalities (Except for human immunodeficiency virus [HIV] infection/HIV infection), including: Those who are receiving immunosuppressants (including chemotherapy) (using medium/high doses of glucocorticoids (≥20mg/d or ≥0.5mg/kg/d), medication time>14 days) or immunoenhancers within 3 days before the skin test or during the trial, and those who are assessed by the researchers to affect the efficacy of the participants; Note: For glucocorticoid drugs: topical inhalation, nasal spray, local injection, application and other external use, as well as long-term physiological replacement therapy for systemic medication such as oral, intramuscular injection, intravenous injection or intravenous drip, there are no restrictions, such as prednisone or other equivalent doses of other drugs at a dose of <20mg/d (>5 years old) or <0.5mg/kg/d (≤5 years old), medication time ≤14 days.
2. Patients with convulsions, epilepsy, history of mental illness and/or family history of mental illness (immediate relatives);
3. Patients with allergic constitution, such as those with a history of allergy to two or more drugs or foods, or those known to be allergic to the components of this drug;
4. Patients with acute infectious diseases (such as measles, whooping cough, influenza, etc.), acute conjunctivitis, acute otitis media, and extensive skin diseases;
5. Patients with severe skin infections (such as pyoderma, severe eczema, etc.);
6. Patients who have used other clinical trial drugs within 3 months before the skin test (except placebo, in vitro diagnostic reagents or non-human contact devices);
7. Patients who have received inactivated vaccines within 7 days before the skin test, or attenuated live vaccines within 28 days;
8. Women who are breastfeeding or pregnant, or women of childbearing age who have a positive pregnancy test before enrollment.
9. Patients with a history of drug abuse;
10. Any situation that the researcher believes has poor compliance, past history, and physical examination results may affect the trial evaluation (such as tattoos, etc.).

Trial design

Primary purpose: Diagnostic

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Quadruple Blind

---

1,784 participants in 7 patient groups

Community-dwelling population aged 3 - 64 years old

Experimental group

Description:

415 Community-dwelling population subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (EC); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 unit（U） EC

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

Community-dwelling population aged above 18 years old

Experimental group

Description:

334 Community-dwelling population subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (TB-PPD); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 IU TB-PPD

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

BCG vaccination subjects in triple-negative population

Experimental group

Description:

Cohort 2 is a healthy group of participants (i.e., triple-negative people) whose test results (including EEC and TB-PPD) and IGRA are negative in both arms after the first skin test. 80 triple-negative people are planned to be included. If they meet the eligibility criteria for BCG vaccination, they will be vaccinated with BCG within 3 weeks after the first skin test, and the second skin test will be conducted again 12 weeks after vaccination. During the second skin test, participants will be randomly injected with a single intradermal injection of 0.1 ml of the test drugs EEC and TB-PPD in each arm.

Treatment:

Biological: 5 IU TB-PPD

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

TB subjects in 3-64 years old

Experimental group

Description:

300 TB subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (EC); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 unit（U） EC

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

TB subjects above 65 years old

Experimental group

Description:

235 TB subjects's left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (TB-PPD); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 IU TB-PPD

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

non-TB subjects with lung disease in 18-65 years old

Experimental group

Description:

300 non-TB subjects with lung disease left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (EEC); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 unit（U） EC

Diagnostic Test: IGRA

Biological: 5μg/ml EEC

non-TB subjects with lung disease above 65 years old

Experimental group

Description:

200 non-TB subjects with lung disease left and right arms were randomly assigned to receive a single intradermal injection of 0.1 ml of the test drug (EEC 5 μg /ml ) and the control drug (TB-PPD); all subjects were intradermally injected into the middle and lower 1/3 of the volar side of the forearm using the Mantoux method. injection. The time between skin tests on the left and right arms must be at least 30 minutes (skin test on the left arm first, then on the right arm). The follow-up visit observation point is based on the completion time of the second dose of injection.

Treatment:

Biological: 5 IU TB-PPD

Diagnostic Test: IGRA

Biological: 5μg/ml EEC